Henan Lingrui Pharmaceutical Co (SHSE:600285) Other Stockholders Equity: ¥696 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600285 Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
87 GF Score
Price ¥21.91
GF Value ¥24.47
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Henan Lingrui Pharmaceutical Co Other Stockholders Equity?

Henan Lingrui Pharmaceutical Co SHSE:600285 -3.10% 87 Other Stockholders Equity is ¥696 Mil as of Mar. 2026. GuruFocus rates SHSE:600285 with a GF Score™ of 87/100 and a GF Value™ of ¥24.47 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Henan Lingrui Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥696 Mil.

Henan Lingrui Pharmaceutical Co's quarterly Other Stockholders Equity declined from Sep. 2025 (¥650 Mil) to Dec. 2025 (¥379 Mil) but then increased from Dec. 2025 (¥379 Mil) to Mar. 2026 (¥696 Mil).

Henan Lingrui Pharmaceutical Co's annual Other Stockholders Equity declined from Dec. 2023 (¥374 Mil) to Dec. 2024 (¥309 Mil) but then increased from Dec. 2024 (¥309 Mil) to Dec. 2025 (¥379 Mil).

Henan Lingrui Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Henan Lingrui Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Lingrui Pharmaceutical Co Other Stockholders Equity Chart

Henan Lingrui Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 360.67 407.59 374.17 309.35 379.25

Henan Lingrui Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 637.81 329.81 649.69 379.25 695.78
SHSE:600285
87GF Score
Henan Lingrui Pharmaceutical Co Ltd SHSE:600285
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Lingrui Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥696 Mil mean?
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a Other Stockholders Equity of ¥696 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Henan Lingrui Pharmaceutical Co and its competitors.
Is Henan Lingrui Pharmaceutical Co's Other Stockholders Equity too high?
Henan Lingrui Pharmaceutical Co's current Other Stockholders Equity is ¥696 Mil. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's Other Stockholders Equity compare to ZTS and UTHR?
Henan Lingrui Pharmaceutical Co's Other Stockholders Equity of ¥696 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. Henan Lingrui Pharmaceutical Co's current Other Stockholders Equity is ¥696 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥24.47, compared to a current price of ¥21.91 — trading 10.5% below its estimated fair value. The current Other Stockholders Equity is ¥696 Mil. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current Other Stockholders Equity is ¥696 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥21.91 is trading 10.5% below its estimated GF Value™ of ¥24.47. GuruFocus considers Henan Lingrui Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600285:

  • Other Stockholders Equity: ¥696 Mil
  • GF Value™: ¥24.47 vs. price of ¥21.91 (10.5% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Henan Lingrui Pharmaceutical Co Business Description

Address No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
87GF Score

Get the complete analysis for SHSE:600285

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.91
Price
¥24.47
GF Value